Discontinued — last reported Q2 '24

Current Assets

Available-for-Sale Debt Securities - Fair Value by Maturity

Biogen Available-for-Sale Debt Securities - Fair Value by Maturity increased by 10.2% to $1.37B in Q1 2026 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement
SectionCurrent Assets
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ3 2017
Last reportedQ2 2024

How to read this metric

A shift toward longer maturities may indicate a search for higher yields, while shorter maturities suggest a defensive posture against rising interest rates.

Detailed definition

This metric provides a breakdown of the fair value of available-for-sale debt securities categorized by their contractua...

Peer comparison

Standard disclosure in the investment securities note for all banks.

Metric ID: afs_debt_securities_fair_value_by_maturity

Historical Data

3 periods
 Q3 '25Q4 '25Q1 '26
Value$97.60M$1.24B$1.37B
QoQ Change—>999%+10.2%
Range$97.60M – $1.37B
Current Streak2+ quarters growth

Frequently Asked Questions

What is Biogen's available-for-sale debt securities - fair value by maturity?
Biogen (BIIB) reported available-for-sale debt securities - fair value by maturity of $1.37B in Q1 2026.
What does available-for-sale debt securities - fair value by maturity mean?
The fair value of investment debt securities organized by when they are scheduled to mature.